Table 1.
Baseline characteristics and perioperative results of RS-RARP and S-RARP cohorts
| RS-RARP (N = 60) |
S-RARP (N = 57) |
p value | |
|---|---|---|---|
| Age (yr), mean | 61.4 | 61.1 | 0.811 |
| BMI (kg/m2), mean | 29.5 | 27.9 | 0.066 |
| Charlson Comorbidity Index, mean | 4.0 | 3.9 | 0.510 |
| Preoperative PSA, mean | 7.9 | 8.8 | 0.470 |
| Preoperative Gleason group, n (%) | |||
| 1 | 9 (15.0) | 19 (33.3) | 0.038 |
| 2 | 21 (35.0) | 22 (38.6) | |
| 3 | 15 (25.0) | 10 (17.5) | |
| 4 | 13 (21.7) | 3 (5.3) | |
| 5 | 2 (3.3) | 3 (5.3) | |
| Preop potency, n (%) | 60 (100.0) | 60 (100.0) | 1.000 |
| Preop EPIC-CP sexual function score, mean | 3.0 | 2.5 | 0.391 |
| Any nerve sparing, n (%) | 51 (85.0) | 48 (84.2) | 0.907 |
| EBL (ml), mean | 187 | 325 | 0.000 |
| Console time (min), mean | 128 | 128 | 1.000 |
| Postoperative complication, n (%) | 4 (6.8) | 7 (12.3) | 0.316 |
BMI = body mass index; EBL = estimated blood loss; EPIC-CP = Expanded Prostate Cancer Index for Clinical Practice; Preop = preoperative; PSA = prostate-specific antigen; RS-RARP = Retzius-sparing robotic-assisted radical prostatectomy; S-RARP = standard robotic-assisted radical prostatectomy.